Chemotherapy at the End of Life – The Reality of an Oncological Centre

Raquel Fontes; Jorge Rodrigues; Camila Oliveira; Mauricio Peixoto; Sonia Doria; Rafael Silva; Sofia Martins; Julia Amorim; Rui Nabiço; Ana Marques

doi:doi:10.11648/j.jctr.20221002.12

Chemotherapy at the End of Life – The Reality of an Oncological Centre

Raquel Fontes, Jorge Rodrigues, Camila Oliveira, Mauricio Peixoto, Sonia Doria, Rafael Silva, Sofia Martins, Julia Amorim, Rui Nabiço, Ana Marques

Published in Journal of Cancer Treatment and Research (Volume 10, Issue 2)

Received: 15 April 2022 Accepted: 4 May 2022 Published: 24 May 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: In advanced and incurable cancer disease, chemotherapy may be recommended if it improves the quality of life, even if it does not increase survival. However, in an end-of-life setting, the use of chemotherapy is controversial, with less clear indications and more individualized decisions. This study aimed to evaluate patients who received chemotherapy within the last three months of life, an indicator of the quality of care provided. Methods: We analyzed data from patients receiving chemotherapy in the last 3 months of life and who died from January 2018 to December 2020, in our Oncology Department. Results: It was found that 391 patients received chemotherapy in the last 3 months of life. Most had metastatic disease at diagnosis (71%, n=276) and were treated in a first-line setting. A more detailed analysis revealed that 50% (n=193) underwent treatment in the last month and 22% (n=42) in the last week of life. Most patients died due to disease progression, with 79% of deaths occurring in the hospital. Conclusions: This work puts into figures the reality of an Oncology Centre, revealing the investment made in fighting the disease and providing greater longevity to patients, with quality of life.

Published in	Journal of Cancer Treatment and Research (Volume 10, Issue 2)
DOI	10.11648/j.jctr.20221002.12
Page(s)	18-23
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Chemotherapy, End of Life, Last Month of Life, Palliative Care

References

[1]	Zhang Z, Chen ML, Gu XL, et al. (2018) Palliative Chemotherapy Near the End of Life in Oncology Patients. Am J Hosp Palliat Care 35 (9): 1215-1220. DOI: 10.1177/1049909118763338.
[2]	Barbera L, Seow H, Sutradhar R, et al. (2015) Quality Indicators of End-of-Life Care in Patients With Cancer: What Rate Is Right? J Oncol Pract. 11 (3): e279-e287. DOI: 10.1200/JOP.2015.004416.
[3]	Earle CC, Neville BA, Landrum MB, et al. (2004) Trends in the Aggressiveness of Cancer Care Near the End of Life. J Clin Oncol 22: 315-321. DOI: 10.1200/JCO.2004.08.136.
[4]	Roser M, Ritchie H, et al. (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet vol 390: 1151–210.
[5]	Assi T, Rassy E, Tabchi S. (2016) Treatment of cancer patients in their last month of life: aimless chemotherapy. Support Care Cancer 24, 1603–1608. DOI 10.1007/s00520-015-2959-3.
[6]	Martins-Branco D, Lopes S, Canario R, et al. (2020) Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal. ESMO Open 2020; 5: e000953. DOI: 10.1136/esmoopen-2020-000953.
[7]	Rochigneux P, Raoul JL, Y. Beaussant Y. (2016) Use of chemotherapy near the end of life: what factors matter? Annals of Oncology 28: 809–817, 2017. DOI: 10.1093/annonc/mdw654.
[8]	Prigerson HG, Bao Y, Shah MA. (2015) Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 1 (6): 778-784. DOI: 10.1001/jamaoncol.2015.2378.
[9]	Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. (2011) Palliative chemotherapy during the last month of life. Annals of Oncology 22: 2375–2380. DOI: 10.1093/annonc/mdq778.
[10]	Stone PC, Lund S. (2007) Predicting prognosis in patients with advanced cancer. Annals of Oncology 18: 971–976. DOI: 10.1093/annonc/mdl343.
[11]	Wilkerson DH, Santos JL, Tan X, Gomez TH. (2021) Too Much Too Late? Chemotherapy Administration at the End of Life: A Retrospective Observational Study. American Journal of Hospice and Palliative Medicine 38 (10): 1182-1188. DOI: 10.1177/1049909120966619.
[12]	Pacetti P, Paganini G, Orlandi M, et al. (2015) Chemotherapy in the last 30 days of life of advanced cancer patients. Support Care Cancer 23 (11): 3277-80. Doi: 10.1007/s00520-015-2733-6.
[13]	Kao S, Shafiq J, Vardy J, Adams D. (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol. 20 (9): 1555-1559. DOI: 10.1093/annonc/mdp027.
[14]	Adam H, Hug S, Bosshard G. (2014) Chemotherapy near the end of life: a retrospective single-centre analysis of patients’ charts. BMC Palliat Care 13, 26. DOI: 10.1186/1472-684X-13-26.
[15]	Andreis F, Rizzi A, et al. (2011) Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori; 97 (1): 30-4. PMID: 21528660.
[16]	Braga S, Miranda A, Fonseca R, et al. (2007) The aggressiveness of cancer care in the last three months of life: A retrospective single centre analysis. Psycho-Oncology 16: 863–868. DOI: 10.1002/pon.1140.
[17]	Urvay S, Civelek B, Ozaslan E et al. (2020) Chemotherapy at the end of life. Journal od Palliative Care 1-5; 36 (2): 73-77. DOI: 10.1177/0825859720946505.
[18]	Heyland DK, Dodek P, Rocker G, et al. (2006) What matters most in end-of-life care: perceptions of seriously ill patients and their family members. CMAJ. 174 (5): 627–633. DOI: 10.1503/cmaj.050626.
[19]	Earle CC, Park ER, Lai B, et al. (2003) Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data. Journal of Clinical Oncology, Vol 21, No 6, pp 1133-1138. DOI: 10.1200/JCO.2003.03.059.
[20]	Luta X, Maessen M, Egger M, et al. (2015) Measuring Intensity of End of Life Care: A Systematic Review. PLoS ONE 10 (4): e0123764. DOI: 10.1371/journal.pone.0123764.
[21]	Braga S. (2011) Why do our patients get chemotherapy until the end of life? Ann Oncol. 22 (11): 2345-2348. DOI: 10.1093/annonc/mdr416.
[22]	Triplett DP, LeBrett WG, Bryant AK, et al. (2017) Effect of Palliative Care on Aggressiveness of End-of-Life Care Among Patients With Advanced Cancer. Journal of Oncology Practice 13, no. 9 (September 01, 2017) e760-e769. DOI: 10.1200/JOP.2017.020883.
[23]	World Health Organization (August, 2020). Palliative Care. https://www.who.int/news-room/fact-sheets/detail/palliative-care.
[24]	Ferrell BR, Temel JS, Temin S et al. (2017) Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 35 (1): 96-112. DOI: 10.1200/JCO.2016.70.1474. Alimehmeti, I. (2021). Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2. Albanian Journal Of Trauma And Emergency Surgery, 5 (1), 791-796. doi: 10.32391/ajtes.v5i1.178.

Cite This Article

Plain Text BibTeX RIS

APA Style

Raquel Fontes, Jorge Rodrigues, Camila Oliveira, Mauricio Peixoto, Sonia Doria, et al. (2022). Chemotherapy at the End of Life – The Reality of an Oncological Centre. Journal of Cancer Treatment and Research, 10(2), 18-23. https://doi.org/10.11648/j.jctr.20221002.12

Copy | Download

ACS Style

Raquel Fontes; Jorge Rodrigues; Camila Oliveira; Mauricio Peixoto; Sonia Doria, et al. Chemotherapy at the End of Life – The Reality of an Oncological Centre. J. Cancer Treat. Res. 2022, 10(2), 18-23. doi: 10.11648/j.jctr.20221002.12

Copy | Download

AMA Style

Raquel Fontes, Jorge Rodrigues, Camila Oliveira, Mauricio Peixoto, Sonia Doria, et al. Chemotherapy at the End of Life – The Reality of an Oncological Centre. J Cancer Treat Res. 2022;10(2):18-23. doi: 10.11648/j.jctr.20221002.12

Copy | Download

@article{10.11648/j.jctr.20221002.12,
  author = {Raquel Fontes and Jorge Rodrigues and Camila Oliveira and Mauricio Peixoto and Sonia Doria and Rafael Silva and Sofia Martins and Julia Amorim and Rui Nabiço and Ana Marques},
  title = {Chemotherapy at the End of Life – The Reality of an Oncological Centre},
  journal = {Journal of Cancer Treatment and Research},
  volume = {10},
  number = {2},
  pages = {18-23},
  doi = {10.11648/j.jctr.20221002.12},
  url = {https://doi.org/10.11648/j.jctr.20221002.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20221002.12},
  abstract = {Background: In advanced and incurable cancer disease, chemotherapy may be recommended if it improves the quality of life, even if it does not increase survival. However, in an end-of-life setting, the use of chemotherapy is controversial, with less clear indications and more individualized decisions. This study aimed to evaluate patients who received chemotherapy within the last three months of life, an indicator of the quality of care provided. Methods: We analyzed data from patients receiving chemotherapy in the last 3 months of life and who died from January 2018 to December 2020, in our Oncology Department. Results: It was found that 391 patients received chemotherapy in the last 3 months of life. Most had metastatic disease at diagnosis (71%, n=276) and were treated in a first-line setting. A more detailed analysis revealed that 50% (n=193) underwent treatment in the last month and 22% (n=42) in the last week of life. Most patients died due to disease progression, with 79% of deaths occurring in the hospital. Conclusions: This work puts into figures the reality of an Oncology Centre, revealing the investment made in fighting the disease and providing greater longevity to patients, with quality of life.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Chemotherapy at the End of Life – The Reality of an Oncological Centre
AU  - Raquel Fontes
AU  - Jorge Rodrigues
AU  - Camila Oliveira
AU  - Mauricio Peixoto
AU  - Sonia Doria
AU  - Rafael Silva
AU  - Sofia Martins
AU  - Julia Amorim
AU  - Rui Nabiço
AU  - Ana Marques
Y1  - 2022/05/24
PY  - 2022
N1  - https://doi.org/10.11648/j.jctr.20221002.12
DO  - 10.11648/j.jctr.20221002.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 18
EP  - 23
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20221002.12
AB  - Background: In advanced and incurable cancer disease, chemotherapy may be recommended if it improves the quality of life, even if it does not increase survival. However, in an end-of-life setting, the use of chemotherapy is controversial, with less clear indications and more individualized decisions. This study aimed to evaluate patients who received chemotherapy within the last three months of life, an indicator of the quality of care provided. Methods: We analyzed data from patients receiving chemotherapy in the last 3 months of life and who died from January 2018 to December 2020, in our Oncology Department. Results: It was found that 391 patients received chemotherapy in the last 3 months of life. Most had metastatic disease at diagnosis (71%, n=276) and were treated in a first-line setting. A more detailed analysis revealed that 50% (n=193) underwent treatment in the last month and 22% (n=42) in the last week of life. Most patients died due to disease progression, with 79% of deaths occurring in the hospital. Conclusions: This work puts into figures the reality of an Oncology Centre, revealing the investment made in fighting the disease and providing greater longevity to patients, with quality of life.
VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Raquel Fontes

Oncology Department, Hospital of Braga, Braga, Portugal
Jorge Rodrigues

Oncology Department, Hospital of Braga, Braga, Portugal
Camila Oliveira

Oncology Department, Hospital of Braga, Braga, Portugal
Mauricio Peixoto

Oncology Department, Hospital of Braga, Braga, Portugal
Sonia Doria

National Oncology Registry Department, Hospital of Braga, Braga, Portugal
Rafael Silva

National Oncology Registry Department, Hospital of Braga, Braga, Portugal
Sofia Martins

National Oncology Registry Department, Hospital of Braga, Braga, Portugal
Julia Amorim

Oncology Department, Hospital of Braga, Braga, Portugal
Rui Nabiço
Ana Marques

Oncology Department, Hospital of Braga, Braga, Portugal

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Raquel Fontes, Jorge Rodrigues, Camila Oliveira, Mauricio Peixoto, Sonia Doria, et al. (2022). Chemotherapy at the End of Life – The Reality of an Oncological Centre. Journal of Cancer Treatment and Research, 10(2), 18-23. https://doi.org/10.11648/j.jctr.20221002.12

Copy | Download

ACS Style

Raquel Fontes; Jorge Rodrigues; Camila Oliveira; Mauricio Peixoto; Sonia Doria, et al. Chemotherapy at the End of Life – The Reality of an Oncological Centre. J. Cancer Treat. Res. 2022, 10(2), 18-23. doi: 10.11648/j.jctr.20221002.12

Copy | Download

AMA Style

Raquel Fontes, Jorge Rodrigues, Camila Oliveira, Mauricio Peixoto, Sonia Doria, et al. Chemotherapy at the End of Life – The Reality of an Oncological Centre. J Cancer Treat Res. 2022;10(2):18-23. doi: 10.11648/j.jctr.20221002.12

Copy | Download

@article{10.11648/j.jctr.20221002.12,
  author = {Raquel Fontes and Jorge Rodrigues and Camila Oliveira and Mauricio Peixoto and Sonia Doria and Rafael Silva and Sofia Martins and Julia Amorim and Rui Nabiço and Ana Marques},
  title = {Chemotherapy at the End of Life – The Reality of an Oncological Centre},
  journal = {Journal of Cancer Treatment and Research},
  volume = {10},
  number = {2},
  pages = {18-23},
  doi = {10.11648/j.jctr.20221002.12},
  url = {https://doi.org/10.11648/j.jctr.20221002.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20221002.12},
  abstract = {Background: In advanced and incurable cancer disease, chemotherapy may be recommended if it improves the quality of life, even if it does not increase survival. However, in an end-of-life setting, the use of chemotherapy is controversial, with less clear indications and more individualized decisions. This study aimed to evaluate patients who received chemotherapy within the last three months of life, an indicator of the quality of care provided. Methods: We analyzed data from patients receiving chemotherapy in the last 3 months of life and who died from January 2018 to December 2020, in our Oncology Department. Results: It was found that 391 patients received chemotherapy in the last 3 months of life. Most had metastatic disease at diagnosis (71%, n=276) and were treated in a first-line setting. A more detailed analysis revealed that 50% (n=193) underwent treatment in the last month and 22% (n=42) in the last week of life. Most patients died due to disease progression, with 79% of deaths occurring in the hospital. Conclusions: This work puts into figures the reality of an Oncology Centre, revealing the investment made in fighting the disease and providing greater longevity to patients, with quality of life.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Chemotherapy at the End of Life – The Reality of an Oncological Centre
AU  - Raquel Fontes
AU  - Jorge Rodrigues
AU  - Camila Oliveira
AU  - Mauricio Peixoto
AU  - Sonia Doria
AU  - Rafael Silva
AU  - Sofia Martins
AU  - Julia Amorim
AU  - Rui Nabiço
AU  - Ana Marques
Y1  - 2022/05/24
PY  - 2022
N1  - https://doi.org/10.11648/j.jctr.20221002.12
DO  - 10.11648/j.jctr.20221002.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 18
EP  - 23
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20221002.12
AB  - Background: In advanced and incurable cancer disease, chemotherapy may be recommended if it improves the quality of life, even if it does not increase survival. However, in an end-of-life setting, the use of chemotherapy is controversial, with less clear indications and more individualized decisions. This study aimed to evaluate patients who received chemotherapy within the last three months of life, an indicator of the quality of care provided. Methods: We analyzed data from patients receiving chemotherapy in the last 3 months of life and who died from January 2018 to December 2020, in our Oncology Department. Results: It was found that 391 patients received chemotherapy in the last 3 months of life. Most had metastatic disease at diagnosis (71%, n=276) and were treated in a first-line setting. A more detailed analysis revealed that 50% (n=193) underwent treatment in the last month and 22% (n=42) in the last week of life. Most patients died due to disease progression, with 79% of deaths occurring in the hospital. Conclusions: This work puts into figures the reality of an Oncology Centre, revealing the investment made in fighting the disease and providing greater longevity to patients, with quality of life.
VL  - 10
IS  - 2
ER  -

Copy | Download